Cristina graduated in Biology at Universidad Complutense de Madrid in 1994. She started her scientific career as an undergraduate student at the laboratory of Dr. Ramos and Dr. Fernández-Ruiz (School of Medicine, Complutense University), where she first took contact with the field of cannabinoid research. Once graduated, she moved to Dr. Guzmán’s laboratory (School of Biology, Complutense University), where she studied the effect of cannabinoids on lipid and carbohydrate intermediate metabolism first and on cancer cell proliferation later. She obtained her PhD with Honors in Biochemistry and Molecular Biology at Universidad Complutense de Madrid in 2000. During her postdoc at Dr. Piomelli’s laboratory (University of California Irvine, 2000-2003) she studied the involvement of another group of bioactive lipids (lysophosphatidic acid and related compounds) on pain initiation. In 2004, Cristina returned to Spain with a “Ramón y Cajal” contract (aimed at repatriating Spanish researchers from abroad) and she started coordinating a new line of research within Dr. Guzmán’s laboratory.
The goal of her research group is to understand the role of the endocannabinoid system in breast cancer, and to exploit this knowledge to provide new therapeutic targets and options for the treatment of this pathology, as well as new patient screening tools (with prognostic and predictive value).
Cristina is the current Vice President of the Spanish Cannabinoid Research Society, Secretary and founding member of the Spanish Observatory on Medical Cannabis and Vice Dean of Research of the School of Biology at Complutense University.
Eduardo graduated in Biochemistry at Universidad Autónoma de Madrid in 2002. He obtained his PhD (Extraordinary Prize) from the Biomedical Research Institute (IIBM), Biology of Cancer department in 2007. During his PhD work, he investigated the role of endoglin, a TGFbeta co-receptor, as a suppressor of malignancy during carcinogenesis. He joined our lab in October 2009. He is now focused on the study of cannabinoid receptors and breast cancer using, as a major tool, mouse models. In 2020 he became an Associate Professor, position that he currently holds.
Sandra graduated in Biology from Complutense University of Madrid in 2012. She started her research experience as an undergraduate student in the lab of Prof. Doorus Gadella (University of Amsterdam). In 2013, she did a Master´s Degree in Biochemistry, Molecular Biology and Biomedicine. During this period, she join our lab where she also completed her PhD in November 2018. Her research focused on the role of the CB2 cannabinoid receptor in breast cancer physiopathology and the use of cannabinoids as potential antitumour agents. In February 2020, Sandra joined the Dr. Sánchez-Danés group at Champalimaud Foundation (Lisbon, Portugal) to study the mechanisms involved in basal cell carcinoma progression. After one year of postdoctoral stay abroad, Sandra has recently returned to our lab to explore the role of the endocannabinoid system in the tumor microenvironment.
Isabel graduated in Health Biology at Universidad de Alcalá (Spain) in 2015. Later that year, she enrolled the MSc in Molecular Biomedicine from the Autonomous University of Madrid (Spain). For her MSc Thesis, she moved to the German Cancer Research Center (DKFZ) in Heidelberg, where she studied the role of the tumor suppressor gene NF1 in tumor migration. In 2016, she joined our lab thanks to a PFIS predoctoral contract from the Carlos III Health Institute. She is now working on her PhD project, aimed at exploring how the endocannabinoid system can be related to the mammary gland development and to the onset and progression of breast tumors.
Marta graduated in Biology at Universidad de Vigo in 2016. Then, in the academic course 2016-2017 she did her Master’s Degree in Biochemistry, Molecular Biology and Biomedicine at the Complutense University of Madrid. During this period, she joined our group to perform her Master’s Thesis. Currently, she is studying Cannabis sativa whole-plant extracts as better therapeutic tools than pure cannabinoids in preclinical models of breast cancer with a PhD grant from Hospital 12 de Octubre.
María graduated in Biochemistry at Universidad Complutense de Madrid in 2020 and she is now studying her Master’s Degree in Immunology Research at the same university. She joined our group to perform her Final Degree Project and is still working on her Master’s Thesis on the possible involvement of the endocannabinoid system in the resistance to anti-HER2 therapies in breast cancer.